Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q1 FY27 results · Apr–Jun 2026
Tatva Chintan Pharma Chem reported revenue from operations of ₹167.06 crore (up 42.9% from Q1 FY26) and net profit of ₹15.98 crore (up 140.3% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 167.06 | 116.86 | +42.9% | 134.14 | +24.5% |
| Other income | 2.78 | 1.16 | +140.7% | (0.35) | Turned profit |
| Total income | 169.84 | 118.02 | +43.9% | 133.80 | +26.9% |
| Profit before tax | 21.11 | 9.10 | +132.0% | 16.59 | +27.3% |
| Net profit for the period | 15.98 | 6.65 | +140.3% | 10.32 | +54.8% |
| EPS, basic (₹) | 6.83 | 2.84 | +140.5% | 4.41 | +54.9% |
| Net margin (%) | 9.6 | 5.7 | 7.7 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 146.70 | 109.18 | +34.4% | 132.66 | +10.6% |
| Other income | 4.03 | 1.37 | +194.6% | (0.37) | Turned profit |
| Total income | 150.74 | 110.55 | +36.4% | 132.30 | +13.9% |
| Profit before tax | 14.09 | 7.05 | +99.8% | 14.97 | −5.9% |
| Net profit for the period | 10.45 | 5.13 | +103.5% | 9.02 | +15.8% |
| EPS, basic (₹) | 4.47 | 2.19 | +104.1% | 3.86 | +15.8% |
| Net margin (%) | 7.1 | 4.7 | 6.8 |
Consolidated
- Filed with BSE
- 17 Jul 2026, 20:18 IST
- Board meeting
- 17 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 Jul 2026, 20:18 IST
- Board meeting
- 17 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE